Study: Erbitux prolongs survival of colon cancer patients

11/14/2007 | Forbes · Bloomberg

The Phase III clinical trial of ImClone Systems' Erbitux found that, when used alone, the drug extended the lives of patients with metastatic colon cancer who have stopped responding to conventional chemotherapy. "These data demonstrate that Erbitux may provide certain colorectal cancer patients with additional time even when other available treatment options have failed," one oncologist said.

View Full Article in:

Forbes · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY